UNMET NEEDS REMAIN IN TREATMENT1

Patients aredissatisfied withtraditionaloral therapies1

The MAPP survey revealed unmet needs in treatment:

*Subset of all patients surveyed. Overall, 24% of all patients said they had been prescribed a traditional oral medication for their disease (eg, cyclosporine, methotrexate, acitretin, or fumaric acid esters) at some point since their diagnosis; of these, 43% were receiving therapy and 57% had discontinued use.

66% of psoriatic arthritis patients report comorbidities, which may contribute to difficulties in treatment1

Patients who discontinued traditional oral therapies did so primarily due to concerns about efficacy, safety, and tolerability1

THE HETEROGENEITYOF PSORIATICARTHRITIS ISA MAJOR CHALLENGEIN THE TREATMENTOF DISEASE

†Observational, cross-sectional study (N = 152) conducted at 2 sites in Amsterdam involving patients with psoriatic arthritis on current or previous conventional DMARD, such as methotrexate or leflunomide, or TNF-inhibitor. Disease activity was defined by the treating rheumatologist (an answer of YES to the question: Do you think there is remaining disease activity in this patient, despite current treatment regimen?) based on physical examination at a routine clinical visit and collected outcome measures (VAS-PhysGlobal, VAS-PhysSkin,and BASDAI).

Psoriatic Arthritis

Disclaimer: This is an international website for OTEZLA® (apremilast). The information on this site is not country-specific. It may contain information that is outside the approved indications in the country in which you are located. If you are a US resident, please click on the US residents link at the top of this page.